Pre-Announced Drug Inspections Will Continue At District Offices' Discretion
Executive Summary
A pre-announced inspection program for drugs and biologics will continue at the discretion of FDA district office management.
You may also be interested in...
FDA Systems-Based cGMP Inspection Pilot Program To Begin In January
All cGMP inspections in six FDA districts will use a new systems-based model under a pilot program slated to run from Jan. 1, 2001 through June 30, 2001.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials